Stock market today: Nasdaq closes above 23,000 for first time as tech rebounds
In a challenging market environment, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock has touched a 52-week low, reaching a price level of $110.92. According to InvestingPro data, the company maintains a GREAT financial health score, with a robust current ratio of 3.4x, indicating strong liquidity. This downturn reflects a broader trend for the biopharmaceutical company, which has seen its shares decline by 16.26% over the past year. Despite the decline, InvestingPro analysis suggests the stock is currently undervalued, with management actively buying back shares. The company has demonstrated strong fundamentals with impressive revenue growth of 24.8% over the last twelve months. Investors are closely monitoring the company’s performance, as the current price level could represent a critical support zone or a potential buying opportunity for those who believe in the company’s long-term value proposition. Neurocrine Biosciences, known for its work in neurology and endocrinology, continues to navigate through the volatile biotech sector, which has been under pressure due to regulatory challenges and a shifting healthcare landscape. With a market capitalization of $11.2 billion and multiple additional insights available on InvestingPro, including 8 more exclusive ProTips and a comprehensive Pro Research Report, investors can access deeper analysis to inform their investment decisions.
In other recent news, Neurocrine Biosciences announced a new $500 million share repurchase program, following the completion of a previous $300 million buyback. This decision aligns with the company’s strategy to balance investments in commercial products and R&D while returning capital to shareholders. In its latest earnings report, Neurocrine Biosciences revealed that Ingrezza generated $615 million in revenue for the fourth quarter of 2024, slightly below the consensus estimate of $623 million. The company also missed earnings expectations, reporting a non-GAAP EPS of $1.69 compared to the anticipated $2.02.
Analysts from UBS, Guggenheim, and H.C. Wainwright adjusted their price targets for Neurocrine Biosciences, reflecting a cautious outlook on Ingrezza’s growth trajectory due to competitive pressures and payer dynamics. UBS lowered its price target to $154, maintaining a Buy rating, while Guggenheim reduced its target to $163, also keeping a Buy rating. H.C. Wainwright set a new price target of $185, citing Ingrezza’s favorable risk-benefit profile despite increased competition.
Deutsche Bank (ETR:DBKGn) initiated coverage with a Hold rating and a $138 price target, suggesting that the current market valuation of Neurocrine Biosciences is fair. The bank’s analyst highlighted a conservative sales projection for Ingrezza and Crensessity, compared to consensus estimates. Meanwhile, Neurocrine Biosciences reported $2 million in sales for its newly launched drug, Crenessity, in late December, which H.C. Wainwright viewed as promising. The company is also progressing with its clinical pipeline, planning pivotal trials for its programs in Major Depressive Disorder and schizophrenia in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.